2017 Medical Devices Fund winners announced
The NSW Government announced the winners of the Medical Devices Fund at a ceremony held last month at Parliament House. The program invests in the development and commercialisation of medical devices and related technologies in NSW, with over $6.61 million split between this year’s four lucky winners.
“The NSW Government is taking home-grown medical innovation to the next level, firmly placing this state at the forefront of global health technology,” said NSW Health Minister Brad Hazzard, who announced the winners.
“This fund gives entrepreneurs the opportunity to get game-changing ideas to market, not only keeping medical device companies in NSW, but significantly improving health outcomes and even saving patients’ lives.”
This year’s Medical Device Fund winners are:
- SpeeDx (awarded $2.5 million), for the commercialisation of the first single test worldwide that detects sexually transmitted infections and antibiotic resistance.
- MedLogical Innovations (awarded $1.25 million), whose ProFocal-Rx drug allows more than 30% of prostate cancer patients to have minimally invasive therapy and preserve their prostate gland.
- Baymatob (awarded $1.47 million), whose non-invasive patch Oli is a capable of monitoring pregnancy and labour remotely, allowing for real-time observation.
- Western Sydney Local Health District (awarded $1.39 million), whose Mu Catheter reduces hypertension by de-nerving the renal artery using a transcatheter microwave.
Since it began in 2013, the NSW Medical Devices Fund has awarded more than $41 million for 24 different technologies. For more information on the fund, visit www.health.nsw.gov.au/ohmr/mdf.
High-potency cannabis use leaves a unique mark on DNA
Frequent users of high-potency cannabis have changes in genes related to mitochondrial and immune...
Scaffold-based method for culturing antitumour bacteria
Bacteria-based cancer therapy represents an exciting new treatment option — but in order to...
mpox vaccine appears safe and effective in adolescents
Interim analysis of an mpox vaccine trial has found the vaccine is safe in adolescents and...